Papers - YONEYAMA Tohru
-
Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
Tohru Yoneyama, Hayato Yamamoto, Mihoko Sutoh Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Takuma Narita, Hirotake Kodama, Masaki Momota, Hiroyuki Ito, Shintaro Narita, Fumiyasu Tsushima, Koji Mitsuzuka, Takahiro Yoneyama, Yasuhiro Hashimoto, Wilhelmina Duivenvoorden, Jehonathan H Pinthus, Shingo Kakeda, Akihiro Ito, Norihiko Tsuchiya, Tomonori Habuchi, Chikara Ohyama
The Prostate 81 ( 16 ) 1411 - 1427 2021.9
-
Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Takuma Narita, Shingo Hatakeyama, Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Mitsuru Saito, Shintaro Narita, Toshikazu Tanaka, Daisuke Noro, Noriko Tokui, Takahiro Yoneyama, Yasuhiro Hashimoto, Tomonori Habuchi, Chikara Ohyama
International journal of urology : official journal of the Japanese Urological Association 28 ( 9 ) 899 - 905 2021.9
-
腎臓結石形成に関与する糖鎖変異オステオポンチンの同定
阿南 剛, 米山 徹, 畠山 真吾, 米山 高弘, 橋本 安弘, 佐藤 信, 大山 力
日本腎臓学会誌 63 ( 4 ) 447 - 447 2021.6
-
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.
Kazutaka Okita, Shingo Hatakeyama, Kazuhisa Hagiwara, Yuichiro Suzuki, Toshikazu Tanaka, Daisuke Noro, Noriko Tokui, Naoki Fujita, Sakae Konishi, Teppei Okamoto, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Urologic oncology 39 ( 12 ) 832.e17 - 832.e23 2021.4
-
Narrative review of urinary glycan biomarkers in prostate cancer.
Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa, Hayato Yamamoto, Chikara Ohyama
Translational andrology and urology 10 ( 4 ) 1850 - 1864 2021.4
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Hirotaka Horiguchi, Shingo Hatakeyama, Tohru Yoneyama, Mihoko Sutoh Yoneyama, Toshikazu Tanaka, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Tadashi Yoshizawa, Yasuhiro Hashimoto, Toshiaki Kawaguchi, Chikara Ohyama
Urologic oncology 39 ( 4 ) 238.e9-238.e17 - 238.e17 2021.4
-
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H, Japanese Urological Oncology Group
BMC cancer 21 ( 1 ) 266 2021.3
-
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Yuka Kubota, Shingo Hatakeyama, Tohru Yoneyama, Mihoko Sutoh Yoneyama, Itsuto Hamano, Sakae Konishi, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
World journal of urology 39 ( 9 ) 3265 - 3271 2021.3
-
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study).
Hirotake Kodama, Shingo Hatakeyama, Masaki Momota, Kyo Togashi, Tomoko Hamaya, Itsuto Hamano, Naoki Fujita, Yuta Kojima, Teppei Okamoto, Tohru Yoneyama, Hayato Yamamoto, Kazuaki Yoshikawa, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Urologic oncology 39 ( 3 ) 191.e1-191.e8 - 191.e8 2021.3
-
The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study).
Kyo Togashi, Shingo Hatakeyama, Yuta Kojima, Masaki Momota, Takuma Narita, Hiromichi Iwamura, Itsuto Hamano, Tomoko Hamaya, Naoki Fujita, Teppei Okamoto, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Urologic oncology 39 ( 3 ) 192.e7-192.e14 - 192.e14 2021.3
-
Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).
Hiromichi Iwamura, Shingo Hatakeyama, Masaki Momota, Yuta Kojima, Takuma Narita, Teppei Okamoto, Naoki Fujita, Itsuto Hamano, Kyou Togashi, Tomoko Hamaya, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Translational andrology and urology 10 ( 3 ) 1143 - 1151 2021.3
-
Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer.
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Urologic oncology 39 ( 3 ) 194.e9-194.e16 - 194.e16 2021.3
-
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Naoki Fujita, Shingo Hatakeyama, Kazutaka Okita, Masaki Momota, Takuma Narita, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Urologic oncology 39 ( 3 ) 191.e9-191.e16 - 191.e16 2021.3
-
Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer.
Masayuki Tomioka, Tohru Yoneyama, Yuki Tobisawa, Kota Kawase, Chie Nakai, Manabu Takai, Daiki Kato, Koji Iinuma, Keita Nakane, Kosuke Mizutani, Yasuhiro Hashimoto, Takuya Koie
Translational andrology and urology 10 ( 3 ) 1192 - 1201 2021.3
-
Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Tomoko Hamaya, Shingo Hatakeyama, Toshikazu Tanaka, Yuka Kubota, Kyo Togashi, Shogo Hosogoe, Naoki Fujita, Ayumu Kusaka, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
BJU international 128 ( 4 ) 468 - 476 2021.2
-
Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution.
Takuya Koie, Yasuhiro Hashimoto, Atsushi Imai, Tohru Yoneyama, Yuki Tobisawa, Toshikazu Tanaka, Daisuke Noro, Masaaki Oikawa, Tadashi Suzuki
International urology and nephrology 53 ( 2 ) 275 - 280 2021.2
-
N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.
Hirotake Kodama, Tohru Yoneyama, Toshikazu Tanaka, Daisuke Noro, Yuki Tobisawa, Hayato Yamamoto, Shinichiro Suto, Shingo Hatakeyama, Kazuyuki Mori, Takahiro Yoneyama, Yasuhiro Hashimoto, Ikuko Kakizaki, Shigeyuki Nakaji, Chikara Ohyama
Cancer medicine 10 ( 4 ) 1297 - 1313 2021.2
-
Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Taku Yoshiya, Tsuyoshi Uemura, Takehiro Ishizu, Minoru Suzuki, Shingo Hachinohe, Shintaro Ishiyama, Motohiro Nonaka, Michiko N Fukuda, Chikara Ohyama
BMC cancer 21 ( 1 ) 105 - 105 2021.1
-
Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicenter retrospective study.
Tomoko Hamaya, Shingo Hatakeyama, Toshikazu Tanaka, Yuka Kubota, Kyo Togashi, Shogo Hosogoe, Naoki Fujita, Ayumu Kusaka, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
BJU international 2021.1
-
N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.
Hirotake Kodama, Tohru Yoneyama, Toshikazu Tanaka, Daisuke Noro, Yuki Tobisawa, Hayato Yamamoto, Shinichiro Suto, Shingo Hatakeyama, Kazuyuki Mori, Takahiro Yoneyama, Yasuhiro Hashimoto, Ikuko Kakizaki, Shigeyuki Nakaji, Chikara Ohyama
Cancer medicine 2021.1